Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2026

Primary Completion Date

August 1, 2026

Study Completion Date

November 1, 2026

Conditions

Multiple Sclerosis, Progressive

Interventions

BIOLOGICAL

Amniotic fluid or placental CD117 stem cells

CD117 (c-Kit) positive stem cells, extracted from ethical fetal sources such as amniotic fluid and placental tissue.

Trial Locations (1)

Atrium Health, Charlotte

All Listed Sponsors

lead

Wake Forest University Health Sciences

OTHER

NCT06841068 - Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter